Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 21, 2021 - Issue 1
Submit an article Journal homepage
1,235
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Cost effectiveness of direct acting antivirals in the treatment of hepatitis C in vulnerable populations

Dhruv VermaView further author information
,
Carina AshkarView further author information
&
Sammy SaabView further author information
Pages 9-12 | Received 18 Sep 2020, Accepted 15 Oct 2020, Published online: 28 Oct 2020

References

  • Global health sector strategy on viral hepatitis 2016-2021. Geneva: World Health Organization. 2016 [cited 2020 Sept 15]. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.
  • Thomas DL. Global elimination of chronic hepatitis. N Engl J Med. 2019;380:2041–2050. .
  • Wu T, Konyn PG, Cattaneo AW, et al. New face of hepatitis C. Dig Dis Sci. 2019;64:1782–1788.
  • Saab S, Le L, Saggi S, et al. Toward the elimination of hepatitis C in the United States. Hepatology. 2018;67:2449–2459. .
  • Petruzziello A, Marigliano S, Loquercio G, et al. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824–7840.
  • CDC. Surveillance for Viral Hepatitis-United States 2015. [cited 2020 Sept 15]. https://www.cdc.gov/hepatitis/statistics/2015surveillance/pdfs/2015HepSurveillanceRpt.pdf
  • Spaudling AC, Anderson EJ, Khan MA, et al. HIV and HCV in U.S. prisons and jails: the correctional facility as a bellwether over time for the community’s infections. AIDS Rev. 2017;19:134–147.
  • Spaulding AC, Sharma A, Messina LC, et al. A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. Am J Public Health. 2015;105(5):e51–e57.
  • Tianhua H, Kan L, Roberts M, et al. Prevention of hepatitis C by screening and treatment in U.S Prisons. Ann Internal Med. 2016;164:84–92.
  • Martin NK, Vickerman P, Brew IF, et al. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology. 2016;63:1796–1808.
  • Dalgic OO, Samur S, Spaulding AC, et al. Improved health outcomes from hepatitis C treatment scale-up in spain’s prisons: a cost-effectiveness study. Sci Rep. 2019;9:16849.
  • Marco A, Domínguez-Hernández R, Casado MA. Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain. Rev Esp Sanid Penit. 2020;22:66–74. .
  • Assoumou SA, Tasillo A, Vellozzi C, et al. Cost-effectiveness and budgetary impact of hepatitis c virus testing, treatment, and linkage to care in US prisons. Clin Infect Dis. 2020;70:1388–1396.
  • Liu S, Watcha D, Holodniy M, et al. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014;161:546–553. .
  • van Santen DK, de Vos AS, Matser A, et al. Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, the Netherlands. PLoS One. 2016;11(10): e0163488.
  • Scott N, Iser DM, Thompson AJ, et al. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. J Gastroenterol Hepatol. 2016;31:872–882. .
  • Stevens ER, Nucifora KA, Hagan H, et al. Cost-effectiveness of direct antiviral agents for hepatitis C virus infection and a combined intervention of syringe access and medication-assisted therapy for opioid use disorders in an injection drug use population. Clin Infect Dis. 2020;70:2652–2662.
  • Scott N, McBryde ES, Thompson A, et al. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut. 2017;66:1507–1515.
  • Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1,2,4,5, and 6 infection. N Engl J Med. 2015;373:2599–2607.
  • Brown R, Buti M, Rodrigues L, et al. Glecaprevir/pirentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the Expedition-8 trial. J Hepatol. 2019;72:441–449. .
  • Falade-Nqulia O, Sulkowski M, Merkow A, et al. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepatol. 2018 Mar; 25(3):220–227.
  • Chen Q, Ayer T, Bethea E, et al. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open. 2019;9:e026726.
  • Recommendations for testing, managing, and treating hepatitis C|HCV guidance. https://www.hcvguidelines.org/. Accessed September 15, 2020.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.